Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HLA-B35-restricted immune responses against survivin in cancer patients.

International journal of cancer - 1 Mar 2004

Reker Sine, Becker Jürgen C, Svane Inge Marie, Ralfkiaer Elisabeth, Straten Per-thor, Andersen Mads Hald

Abstract excerpt

Two HLA-A2 restricted epitopes have recently been identified from the broadly expressed tumor antigen survivin, and several vaccination trials in cancer patients based on these survivin-derived peptides have been initiated. Consequently, there is a crucial need for the identification of survivin epitopes restricted to other HLA-molecules in order to extend the proportion of patients that can enter these ongoing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Genes, MHC Class I

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HLA-B35 Antigen

Share to Immunoenzyme Techniques

Share to Inhibitor of Apoptosis Proteins

Share to Lymphocytes, Tumor-Infiltrating

Share to Survivin

Share to T-Lymphocytes, Cytotoxic

Source

Identifiers

PMID: 14712500
DOI: 10.1002/ijc.11634

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HLA-B35-restricted immune responses against survivin in cancer patients.PMID 14712500Read ↗

Mapping and binding analysis of peptides derived from the tumor-associated antigen survivin for eight HLA alleles.Semantic proximity Read ↗

Induction of HLA-DP4-restricted anti-survivin Th1 and Th2 responses using an artificial antigen-presenting cell.Semantic proximity Read ↗

Identification of a novel HLA-A2-restricted mutated Survivin epitope and induction of specific anti-HCC CTLs that could effectively cross-recognize wild-type Survivin antigen.Semantic proximity Read ↗

A tyrosinase peptide presented by HLA-B35 is recognized on a human melanoma by autologous cytotoxic T lymphocytes.Semantic proximity Read ↗

TCR Gene Transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 Epitopes as Melanoma-Specific Immune TargetsSemantic proximity Read ↗

Identification of tumour-associated T-cell epitopes for vaccine development.Semantic proximity Read ↗

Immunological evaluation of peptide vaccination for cancer patients with the HLA -A11+ or -A33+ allele.Semantic proximity Read ↗

Identification of an SSX-2 epitope presented by dendritic cells to circulating autologous CD4+ T cells.Semantic proximity Read ↗

DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model.Semantic proximity Read ↗

A human CTL recognizes a caspase-8-derived peptide on autologous HLA-B*3503 molecules and two unrelated peptides on allogeneic HLA-B*3501 molecules.Semantic proximity Read ↗

HLA-B35 correlates with a favorable outcome following adjuvant administration of an HLA-matched allogeneic melanoma vaccine.Semantic proximity Read ↗

Identification of three non‐VNTR MUC1‐derived HLA‐A*0201‐restricted T‐cell epitopes that induce protective anti‐tumor immunity in HLA‐A2/Kb‐transgenic miceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.